Lexicon Pharmaceuticals
LXRX
105 hedge funds and large institutions have $1.16B invested in Lexicon Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 12 closing their positions.
619% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $1.6M
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
95% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 21
45% more capital invested
Capital invested by funds: $802M → $1.16B (+$360M)
12% more funds holding
Funds holding: 94 → 105 (+11)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$20.9M |
| 3 |
BM
Bridger Management
New York
|
+$11.3M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$10.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
-$6.88M |
| 2 |
SAMH
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
|
-$2.99M |
| 3 |
Renaissance Technologies
New York
|
-$1.74M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.17M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.01M |
LXRX Hedge Fund Activity: Q3 2015 in Review
105 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2015, worth a combined $1.16B — up 45% from $802M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LXRX positions and 12 closed out — a net gain of 12 holders — while 41 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $21M. The largest seller was Masters Capital Management, cutting an estimated $6.88M.
- 105 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2015, up from 94 in Q2 2015.
- Funds reported $1.16B of Lexicon Pharmaceuticals stock for Q3 2015, up 45% quarter-over-quarter.
- 24 funds opened new Lexicon Pharmaceuticals positions in Q3 2015 and 12 closed out, a net change of +12 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2015 was State Street, an estimated $21M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2015 was Masters Capital Management, an estimated $6.88M sold.
Based on aggregated 13F filings for Q3 2015.